drugset / Trial / NCT00062816
Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs
Treatment
Summary
The purposes of this Phase 1/2 study are to examine the safety, tolerability, and antiviral activity of ISIS 14803, when given in combination with peginterferon alfa and ribavirin, to patients who either failed to have at least a 100-fold HCV reduction at Week 12 of standard therapy or still have detectable HCV at Week 24.
Timeline
- Start
- 2003-06
- Primary completion
- 2004-01
- Completion
- 2004-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ISIS 14803 | Unknown | 3 mg/kg | Intravenous |
| Subject | ISIS 14803 | Unknown | 6 mg/kg | Intravenous |
| Background | Peginterferon alfa-2a | Protein / enzyme biologic | — | — |
| Background | Ribavirin | Small molecule | — | — |